CClinicalTrials.gg
CompletedNCT03411525Updated Mar 7, 2019

Effects of Provider Commitments to Choose Wisely

An interventional study of Commitment Invitation for Clinicians (Clinician Intervention) and Health Education Materials to Patients (Patient Intervention) in Health Services Misuse, Physician's Practice Patterns and Guideline Adherence, sponsored by University of Michigan. Completed at 9 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-03-07.

Sponsored by University of Michigan · Not applicable, Interventional, and Health services research

Phase
Not applicable
Study type
Interventional
Enrollment
489
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Clinicians' decisions to order potentially unnecessary services -- such as those targeted in the Choosing Wisely® campaign -- are often affected by their high-pressure practice environments, which can make it hard to consistently avoid ordering low-value care. The field of behavioral economics offers a promising and highly scalable approach to decreasing use of low-value services: asking clinicians to commit to avoid ordering such services and providing them and their patients with resources to support adherence to this commitment. This project will evaluate the effects of such an intervention across 2 large health systems, Michigan Medicine and IHA, through a mixed-methods, stepped wedge cluster randomized trial. In each of the study clinics, clinicians will be invited to commit to following a set of targeted Choosing Wisely® recommendations. Clinicians who make such a commitment, and their patients, will receive access to key resources to support adherence to this commitment. To measure the effects of the intervention, automated clinical data and medical record data before and after the intervention will be examined. Surveys and semi-structured interviews of both clinicians and patients will also be conducted to determine the effects of the intervention on their decision-making and experiences.

Read the detailed description

A mixed-methods stepped wedge cluster randomized trial will be conducted in 8 primary care clinics of IHA, a private multispecialty group practice, and Michigan Medicine, a large academic health system. The study will test whether pre-encounter clinician commitments combined with patient and provider supports decrease overtreatment of type 2 diabetes among patients 65 and older, use of benzodiazepines and sedative-hypnotics among patients age 65 and older who have insomnia or anxiety, and use of PSA tests to screen for prostate cancer among men 75 and older. These 3 recommendations were chosen because they are commonly performed in primary care practice, have Choosing Wisely® recommendations against these low-value services, and represent situations in which clinician decisions about ordering of services can be unduly swayed by interactions with patients.

02

Conditions studied

  • Health Services Misuse
  • Physician's Practice Patterns
  • Guideline Adherence
  • Unnecessary Procedures
  • Health Care Costs
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Clinician participants will be drawn from the pool of physicians, nurse practitioners, and physician assistants staffing the 8 primary care clinics.
  • Patients of all 8 study clinics must meet criteria for one of the three Choosing Wisely® recommendations to be eligible to participate:

    • 65 and older with type 2 diabetes
    • 65 and older with insomnia and/or anxiety
    • male, 75 and older with no history of prostate cancer.

Exclusion criteria

Exclusion Criteria:

  • Patients who have cognitive impairment and/or a serious psychiatric diagnosis will not be eligible to participate in the surveys or interviews.
04

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
489 participants (actual)

Study arms

  • Experimental
    Commitment invitation at time 1

    In the stepped wedge cluster randomized design, the first clinic will remain in the control period (no intervention) for 1 month, followed by a 1 month transition period (where data will not be collected), before crossing over to the intervention period for 8 months.

    Behavioral: Commitment Invitation for Clinicians (Clinician Intervention) · Other: Health Education Materials to Patients (Patient Intervention)

  • Experimental
    Commitment invitation at time 2

    In the stepped wedge cluster randomized design, the second clinic will remain in the control period (no intervention) for 2 months, followed by a 1 month transition period (where data will not be collected), before crossing over to the intervention period for 7 months.

    Behavioral: Commitment Invitation for Clinicians (Clinician Intervention) · Other: Health Education Materials to Patients (Patient Intervention)

  • Experimental
    Commitment invitation at time 3

    In the stepped wedge cluster randomized design, the third clinic will remain in the control period (no intervention) for 3 months, followed by a 1 month transition period (where data will not be collected), before crossing over to the intervention period for 6 months.

    Behavioral: Commitment Invitation for Clinicians (Clinician Intervention) · Other: Health Education Materials to Patients (Patient Intervention)

  • Experimental
    Commitment invitation at time 4

    In the stepped wedge cluster randomized design, the fourth clinic will remain in the control period (no intervention) for 4 months, followed by a 1 month transition period (where data will not be collected), before crossing over to the intervention period for 5 months.

    Behavioral: Commitment Invitation for Clinicians (Clinician Intervention) · Other: Health Education Materials to Patients (Patient Intervention)

  • Experimental
    Commitment invitation at time 5

    In the stepped wedge cluster randomized design, the fifth clinic will remain in the control period (no intervention) for 5 months, followed by a 1 month transition period (where data will not be collected), before crossing over to the intervention period for 4 months.

    Behavioral: Commitment Invitation for Clinicians (Clinician Intervention) · Other: Health Education Materials to Patients (Patient Intervention)

  • Experimental
    Commitment invitation at time 6

    In the stepped wedge cluster randomized design, the sixth clinic will remain in the control period (no intervention) for 6 months, followed by a 1 month transition period (where data will not be collected), before crossing over to the intervention period for 3 months.

    Behavioral: Commitment Invitation for Clinicians (Clinician Intervention) · Other: Health Education Materials to Patients (Patient Intervention)

  • Experimental
    Commitment invitation at time 7

    In the stepped wedge cluster randomized design, the seventh clinic will remain in the control period (no intervention) for 7 months, followed by a 1 month transition period (where data will not be collected), before crossing over to the intervention period for 2 months.

    Behavioral: Commitment Invitation for Clinicians (Clinician Intervention) · Other: Health Education Materials to Patients (Patient Intervention)

  • Experimental
    Commitment invitation at time 8

    In the stepped wedge cluster randomized design, the eighth clinic will remain in the control period (no intervention) for 8 months, followed by a 1 month transition period (where data will not be collected), before crossing over to the intervention period for 1 month.

    Behavioral: Commitment Invitation for Clinicians (Clinician Intervention) · Other: Health Education Materials to Patients (Patient Intervention)

Interventions

  • BehavioralCommitment Invitation for Clinicians (Clinician Intervention)

    Clinicians will be invited to commit to follow 3 Choosing Wisely® recommendations. Those that choose to commit will sign a written document, appear on in-clinic posters along with their colleagues who have committed to the recommendations, have access to point-of-care Choosing Wisely® patient education handouts, and receive weekly emails with decision support resources.

  • OtherHealth Education Materials to Patients (Patient Intervention)

    During the intervention period, the letter and study information sheet that eligible patients will receive in advance of a scheduled appointment with a participating clinician will also be accompanied by a patient education handout from Consumer Reports that is publicly available and may be relevant to their health and health care. Specifically, patients with type 2 diabetes who are 65 and older will receive a handout about diabetes overtreatment, patients with insomnia or anxiety who are 65 and older will receive a handout about overuse of benzodiazepines and sedative-hypnotics, and male patients who are 75 and older with no history of prostate cancer will receive a handout about overuse of PSA tests to screen for prostate cancer.

05

What researchers measure

Primary outcomes

  1. Difference in the proportion of intervention and control period visits with an applicable low-value treatment or test as specified by each respective Choosing Wisely® recommendation

    The applicable low-value treatments or tests specified by the respective Choosing Wisely® recommendations are use of hypoglycemic medications for patients 65 years or older with diabetes and tight glycemic control, PSA testing among men 75 years or older with no history of prostate cancer, and use of benzodiazepine or sedative-hypnotic medications for patients with insomnia or anxiety who are 65 years or older.

    Time frame: 10 months

Secondary outcomes

  1. Patient trust in primary care provider

    Self reported level of trust patient has in his or her primary care provider as measured by a 5-item scale.

    Time frame: Within 1 week of primary care visit

  2. Patient rating of provider

    Patient's self-reported rating of their primary care provider as measured on a 0 to 10 scale.

    Time frame: Within 1 week of primary care visit

  3. Frequency of patient-provider conversations about the applicable low-value treatments or tests

    Self-reported frequency of patient-provider conversations about the applicable low-value treatments or tests. The applicable low-value treatments or tests specified by the respective Choosing Wisely® recommendations are use of hypoglycemic medications for patients 65 years or older with diabetes and tight glycemic control, PSA testing among men 75 years or older with no history of prostate cancer, and use of benzodiazepine or sedative-hypnotic medications for patients with insomnia or anxiety who are 65 years or older.

    Time frame: Within 1 week of primary care visit

  4. Composite difference in the proportion of intervention and control period visits with an applicable low-value treatment or test as specified by each respective Choosing Wisely® recommendation

    The study will combine data from all target recommendations (e.g., a composite outcome) where if one visit meets inclusion criteria for more than one target recommendation, they will be treated as independent visits.

    Time frame: 10 months

06

Study locations

9 sites
  • IHA Family & Internal Medicine - West Arbor
    Ann Arbor, Michigan 48103, United States
  • IHA Internal Medicine - Domino's Farms
    Ann Arbor, Michigan 48105, United States
  • Michigan Medicine Briarwood Medical Group
    Ann Arbor, Michigan 48108, United States
  • Michigan Medicine East Ann Arbor Health and Geriatrics Center
    Ann Arbor, Michigan 48109, United States
  • University of Michigan Medical School
    Ann Arbor, Michigan 48109, United States
  • Michigan Medicine Brighton Health Center
    Brighton, Michigan 48116, United States
  • IHA Family & Internal Medicine - Cherry Hill
    Canton, Michigan 48187, United States
  • Michigan Medicine Canton Health Center
    Canton, Michigan 48187, United States
  • IHA Internal Medicine - Towsley
    Ypsilanti, Michigan 48197, United States
07

Registry details

Key details

Study ID
NCT03411525
Lead sponsor
University of Michigan
Collaborators
Donaghue Medical Research Foundation, Integrated Health Associates
Responsible party
Jeffrey T. Kullgren (Assistant Professor of Internal Medicine, University of Michigan) — Principal investigator
First posted
Jan 26, 2018
Start date
Jan 26, 2018
Primary completion
Nov 1, 2018
Completion
Feb 28, 2019
Last update
Mar 7, 2019

Study contacts

Jeffrey T. Kullgren, MS, MD, MPH
principal investigator · University of Michigan
Eve Kerr, MD, MPH
principal investigator · University of Michigan

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion